Joint Sepsis Solutions Backed by Clinical Evidence

Read complete study: Management of infected shoulder arthroplasty: a comparison of treatment strategies

In 2013, Dr. Carlo Romano presented clinical evidence for InterSpace via a systematic review of globally accumulated literature. Five years later, in 2018, the data was updated to include new publications and 28 peer-reviewed papers found from more than 20 different sites. The review excluded case reports, clinical series with less than 10 patients, duplicate studies, and series with a mean follow-up of less than 24 months. The inclusion criteria left 19 papers for a total of 732 spacers implanted at 18 centers. This systematic review of the literature demonstrates the safe and effective use of InterSpace in overcoming complications associated with Periprosthetic Joint Infection (PJI).

  • Only 43 patients (5.9 percent) had a persistent infection that required a spacer exchange or resection arthroplasty
  • Seven hundred and nine (709) patients underwent the second-stage procedure
  • Of the 709, only 44 patients (6.2 percent) had an infection at the mean follow-up of 55 months.1

InterSpace Infographic showing 709 patients under went second-stage procedure, with 55 months average follow-up and a 93.8 percent eradication rate at latest follow-upToday, the updated clinical results continue to show that the routine use of the InterSpace antibiotic spacers are validated. As a recent example of published clinical results, Patrick et al. from the University of Florida published “Management of infected shoulder arthroplasty: a comparison of treatment strategies” in the Journal of Shoulder and Elbow Surgery. Among the reviewed treatment modalities for infected shoulder arthroplasty, the InterSpace Shoulder was found to be an effective tool across various
treatment strategies.

For additional information regarding Exactech’s infection-related solutions, please contact Andrew Sutherland at (352) 514-3536 or


  1. Data on file at Exactech.